Thompson Davis & CO. Inc. Makes New Investment in LifeMD, Inc. (NASDAQ:LFMD)

Thompson Davis & CO. Inc. bought a new stake in shares of LifeMD, Inc. (NASDAQ:LFMD) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 14,145 shares of the company’s stock, valued at approximately $117,000.

Other large investors also recently modified their holdings of the company. Dorsey Wright & Associates bought a new stake in LifeMD during the third quarter worth $37,000. Worth Venture Partners LLC acquired a new position in shares of LifeMD during the 3rd quarter worth $64,000. Freedom Wealth Alliance LLC bought a new stake in shares of LifeMD during the 3rd quarter worth $68,000. Barclays PLC acquired a new stake in LifeMD in the third quarter valued at about $142,000. Finally, Russell Investments Group Ltd. bought a new position in LifeMD in the fourth quarter valued at about $153,000. 35.52% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts have recently commented on the stock. BTIG Research increased their target price on shares of LifeMD from $13.00 to $14.00 and gave the stock a “buy” rating in a report on Tuesday, April 23rd. HC Wainwright increased their price objective on shares of LifeMD from $10.00 to $12.00 and gave the company a “buy” rating in a research note on Thursday, January 11th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $10.40.

LifeMD Trading Up 0.5 %

Shares of LifeMD stock traded up $0.06 on Tuesday, hitting $11.93. The stock had a trading volume of 603,179 shares, compared to its average volume of 810,688. The stock has a 50 day moving average of $9.51 and a 200 day moving average of $7.81. The firm has a market capitalization of $481.61 million, a P/E ratio of -17.04 and a beta of 1.43. LifeMD, Inc. has a twelve month low of $1.40 and a twelve month high of $12.43. The company has a debt-to-equity ratio of 3.22, a quick ratio of 1.15 and a current ratio of 1.22.

LifeMD (NASDAQ:LFMD) last announced its quarterly earnings results on Monday, March 11th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.02. The business had revenue of $44.86 million during the quarter, compared to analyst estimates of $40.65 million. Sell-side analysts expect that LifeMD, Inc. will post -0.14 earnings per share for the current fiscal year.

LifeMD Company Profile

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.